



NEW DELHI METALLO-B-LACTAMASE 1 (NDM-1) PRODUCING *ESCHERICHIA COLI* IN BASRAH HOSPITALS. IRAQ

Ismael Jmia Abas and Maytham A. Al-Hamdani*

Department of Biology- College of Education for Pure Sciences-Basrah University, Basrah –Iraq.

*Corresponding Author: Maytham A. Al-Hamdani

Department of Biology- College of Education for Pure Sciences-Basrah University, Basrah –Iraq.

Article Received on 16/12/2016

Article Revised on 06/01/2017

Article Accepted on 28/01/2017

ABSTRACT

Resistance to carbapenems is developing around the world *Escherichia coli* (*E.coli*) resistance to carbapenems is associated with production of carbapenem-hydrolyzing class B metallo- β -lactamases (MBL). New Delhi metallo- β -lactamase 1 (NDM-1) is one of the most recently discovered MBL among *E.coli*. The present work was aimed to study the prevalence of bla NDM-1 gene among carbapenem-resistant *E.coli* isolates from six hospitals in Basrah, Iraq. Isolates identified and antibiotics susceptibility were assayed by using VITEK2 Compact. Phenotypic detection of carbapenemase was performed using combined-disc synergy test (CDST), Chrom ID Carba agar and using RAPIDEC CARBA NP test, isolates were also subjected to the polymerase chain reaction detection of bla NDM-1 gene. Phylogenetic analysis showed very less variation in bla NDM-1 gene with respect to bla NDM-1 possessing by different bacteria. Conclusions: Our findings highlight the incidence of bla NDM-1 in *E. coli* isolates with a reduced susceptibility to Imipenem or meropenem.

KEYWORDS: NDM-1, carbapenems, MBLs, *Escherichia coli*, antibiotics resistance.

INTRODUCTION

Carbapenem resistance caused by acquiring the Metallo-beta-lactamases (MBL) is considered to be more serious than other resistance mechanisms because MBLs can almost hydrolyse all beta-lactam antibiotics except monobactams (Rahmati *et al.*, 2013). Recently identified New Delhi MBL-1 (NDM-1) is a new type of carbapenemase belongs to the class B of Ambler β -lactamases produced by certain strains of bacteria, and is able to inactivate all β -lactams except aztreonam (Walsh *et al.*, 2005). It was first reported in *K. pneumoniae* and *Escherichia coli* derived from a Swedish patient of Indian origin who was admitted to hospital in New Delhi, India in 2009 (Yonge *et al.*, 2009). Although NDM-1 producers have been described worldwide, they are mainly recovered from patients who had relationship with the Indian subcontinent (Nordmann *et al.*, 2011) and in some cases with the Balkan states (Livermore *et al.*, 2011) and the Middle East (Poirel *et al.*, 2011).

METHOD AND MATERIAL

Bacterial isolates: Bacterial isolates were recovered from different clinical samples in Some Basrah Hospitals \Iraq during the period from April to August 2016. Bacteria were cultured on MacConkey agar in aerobic condition at 37 °C for 24-48 h, and then identified by conventional biochemical tests and by using of VITEK 2 Automated system using (GN) cards.

Antibiotic susceptibility testing

VITEK 2 system using (AST- GN30) was used, and the MIC values for these isolates were obtained. The susceptibility of the isolates was determined against 15 antibiotics included: Piperacillin (PRL), Piperacillin/Tazobactam (TPZ-TZP), Ceftazidime (CAZ), Cefepime, (FEP), Aztreonam (ATM), imipenem (IMP), Meropenem (MEM), Amikacin (AK), Gentamicin (CN), Netilmicin (NTE), Tobramycin (TOP), Ciprofloxacin (CIP), Levofloxa (LVE), Tetracycline (TE), Trimethoprim/Sulfamethoxazole remaining (SXT).

Phenotype detection of Metallo- β lactamase (MBLs).

Detection of MBLs production among the *Escherichia coli* isolates was done using combined-disc synergy test (CDST). As an inhibition zone with the imipenem-EDTA disc was >7 mm than the zone of inhibition of imipenem alone. Shown in Figure 1.



Figure.1 Combined disk synergy test (CDST) positive for MBL production in *Escherichia coli* isolates,

upper disk, is imipenem+EDTA, and the lower disk is imipenem only.

The detection of carbapenemase production among the *Escherichia coli* isolates was done using Chrom ID Carba agar. A positive result. Which appear as red colonies on Chrom ID Carba agar shown in Figure 2.



Figure. 2 Chrom ID Carba agar positive for carbapenemase producing in *Escherichia coli* isolates,

The other method detection of carbapenemase production among the *Escherichia coli* isolates was done by using RAPIDEC CARBA NP test a positive result which appear as orange or yellow colour in Test well e Figure 3



Figure 3 RAPIDEC CARBA NP test positive for carbapenemase producing in *Escherichia coli* isolates

Preparation of primers suspension

The DNA primers were re suspended by dissolving the lyophilized primers after spinning down with TE buffer depending on manufacturer instruction as stock suspension. Working primer tube was prepared by diluted with TE buffer.

Detection of New Delhi Metallo- β -Lactamase (NDM-1) gene by using PCR

Detection of NDM-1 gene was conducted by using primers for amplification. A fragment 621 bp of NDM

was amplified using a forward primer (NDM-1 F: 5GGTTTGGCGATCTGGTTTTTC 3') and a reverse primer (NDM-1 R: 5' CGGAATGGCTCATCACGATC 3') (Primers set supplied by IDT (Integrated DNA Technologies company, Canada.). The PCR amplification was performed in a total volume of 25 μ l containing 1.5 μ l DNA, 5 μ l Tag PCR Premix (Intron, Korea), 1 μ l of each primer (10 pmol) then distilled water was added into tube to a total volume of 25 μ l. The thermal cycling conditions were done as follows: Denaturation at 94 °C for 3 min, followed by 35 cycles of 94 °C for 45s, 48°C for 35 sec and 72 °C for 35 sec with final incubation at 72 °C for 7 min using a thermal Cycler (Gene Amp, PCR system 9700; Applied Bio system). The PCR products were separated by 1.5% agarose gel electrophoresis and visualized by exposure to ultraviolet light (302nm) after red stain staining (Intron Korea).

The DNA sequences of blaNDM-1

The DNA sequences of blaNDM-1 amplicons obtained in the present study were compared with the four isolates retrieved from theNCBI GenBank database. Nucleotide BLAST (BLASTN) was used for the sequence searches with default parameters.

RESULTS AND DISCUSSION

Eighteen (18) Carbapenem resistant *Escherichia coli* were recovered from different clinical samples urine (8)44.44%, burn (6) 33.33%, blood (2) 11.11% and wound (2) 11.11%. From different hospitals in Basrah ,Iraq The MIC of 15 antibiotics listed in Table 3 was done using VITEK 2-Compact using Interpreted according to the CLSI breakpoints

The Carbapenem-resistant *Escherichia coli* in this study differed in the level of resistance to different antibiotics including the carbapenems (Table 1). All isolates18(100%) showed resist for both imipenem and Meropenem and for Priperacillin, Piperacillin/Tazobactam, Ceftazidime Cefepime, Aztreonam, Netilmicin, Tobramycin while 15(83.3%) isolates showed resist for Gentamicin, Ciprofloxacin, Levofloxa, Trimethoprim/Sulfamethoxazole remaining and 11 (61%) isolates showed resist for Tetracycline while 10(55%) isolates showed resist for Amikacin So in the present study, most isolates show a high level of resistance to all antibiotics including β -lactamase inhibitor, aminoglycosides, and quinolones. This is because β -lactamase producers have enzymes that hydrolysis the active site of the antibiotics, thus making the organism resistance to virtually all β -lactam antibiotics. This enzyme has spread worldwide with intra and interspecies transfer being facilitated by plasmid encoded enzyme. β - lactams are the most widely used antibiotics all over the world and resistance to this antibiotics has resulted in a major clinical crisis (Spanu et al., 2002).

Resistance to Meropenem and Imipenem to was present in all isolates 16 (100%) There is an increase in the resistance against the powerful carbapenems antibiotics because long-term hospitalization. And long term antibiotic use. This is in agreement with the work done by Ullah *et al.*, (2009) who reported susceptibility pattern to imipenem in *Escherichia coli* to be 98% while meropenem was 97%. Many report show carbapenem-resistance in clinical isolates of *E. coli* is increasing (Poirel *et al.*, 2004; Hong *et al.*, 2005; Lartigue *et al.*, 2007; Oteo *et al.*, 2008; Falagas and Karageorgopoulos, 2009),

The low susceptibility of the *E.coli* isolates against many antibiotics in this study may be due to extensive using of these antibiotics in clinical practice in Iraq. Excessive use of broad-spectrum antibiotics in hospitals has led to the emergence of highly resistant strains of *E.coli*. and strong selective pressure posed on bacteria by the use of carbapenems has facilitated the emergence and spread of carbapenemases in β -lactamase classes A, B and D in clinical settings (Nordmann *et al.*, 2011; Cantón, Akóva, *et al.*, 2012) To reduce the selection pressure for resistance, it is an important issue to determine the antibiotic susceptibility pattern of bacteria, so that hospital patients can be treated with more narrow-spectrum and target-specific.

Table: 1 Antibiotic susceptibility of carbapenem-resistant *E.coli* isolates

Bacteria No	PRL	TPZ-TZP	CAZ	FEP	ATM	IMP	MEM	AK	CN	NET	TOB	CIP	LEV	TE	SXT
<i>E.coli</i> 1	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	≥64 (R)	≥16 (R)	≥16 (R)	≤2 (S)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 2	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	32 (R)	≥16 (R)	≥16 (R)	≥64 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	2 (S)	≥320 (R)
<i>E.coli</i> 3	≥128 (R)	≥128 (R)	≥128 (R)	16 (R)	≥64 (R)	≥16 (R)	≥16 (R)	16 (I)	>=1 (S)	≥32 (R)	≥16 (R)	1 (S)	1 (S)	≥16 (R)	<=20 (S)
<i>E.coli</i> 4	≥128 (R)	≥128 (R)	≥128 (R)	≥32 (R)	≥64 (R)	≥16 (R)	8 (R)	≥16 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 5	≥128 (R)	≥128 (R)	≥128 (R)	16 (R)	≥64 (R)	≥16 (R)	≥16 (R)	16 (I)	>=1 (S)	≥32 (R)	≥16 (R)	1 (S)	1 (S)	≥16 (R)	<=20 (S)
<i>E.coli</i> 6	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	32 (R)	≥16 (R)	≥16 (R)	≥64 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	2 (S)	≥320 (R)
<i>E.coli</i> 7	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	≥64 (R)	≥16 (R)	≥16 (R)	≤2 (S)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 8	≥128 (R)	≥128 (R)	≥128 (R)	≥32 (R)	≥64 (R)	≥16 (R)	8 (R)	≥16 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 9	≥128 (R)	≥128 (R)	≥128 (R)	16 (R)	≥64 (R)	≥16 (R)	≥16 (R)	16 (I)	>=1 (S)	≥32 (R)	≥16 (R)	1 (S)	1 (S)	≥16 (R)	<=20 (S)
<i>E.coli</i> 10	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	≥64 (R)	≥16 (R)	≥16 (R)	≤2 (S)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 11	≥128 (R)	≥128 (R)	≥128 (R)	≥32 (R)	≥64 (R)	≥16 (R)	8 (R)	≥16 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 12	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	32 (R)	≥16 (R)	≥16 (R)	≥64 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	2 (S)	≥320 (R)
<i>E.coli</i> 13	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	32 (R)	≥16 (R)	≥16 (R)	≥64 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	2 (S)	≥320 (R)
<i>E.coli</i> 14	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	32 (R)	≥16 (R)	≥16 (R)	≥64 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	2 (S)	≥320 (R)
<i>E.coli</i> 15	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	32 (R)	≥16 (R)	≥16 (R)	≥64 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	2 (S)	≥320 (R)
<i>E.coli</i> 16	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	≥64 (R)	≥16 (R)	≥16 (R)	≤2 (S)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 17	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	≥64 (R)	≥16 (R)	≥16 (R)	≤2 (S)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	≥16 (R)	≥320 (R)
<i>E.coli</i> 18	≥128 (R)	≥128 (R)	≥64 (R)	≥32 (R)	32 (R)	≥16 (R)	≥16 (R)	≥64 (R)	≥16 (R)	≥32 (R)	≥16 (R)	≥4 (R)	≥8 (R)	2 (S)	≥320 (R)

In the present study detection of MBLs production among the *Escherichia coli* isolates was done using combined-disc synergy test (CDST). Only 8 (44.44%) out of 18 *Escherichia coli* isolates showed a positive

result. And to detection of carbapenemase production among the *Escherichia coli* isolates was done using Chrom ID Carba agar 17 (94.44%) out of isolates showed a positive result while by using RAPIDEC CARBA NP

test that all isolated show positive for this test .Table 3, these results agreement with Simner *et al* 2015 who found that ChromID Carba was the most sensitive and

specific chromogenic medium evaluated for the detection of carbapenemase gram negative bacteria.

Table 2 Prevalence of Phenotype method among Clinical isolates of *Escherichia coli*.

Test	CDST	Chrom ID Carba agar	RAPIDEC CARBA NP
Positive	8 (44.44%)	17(94.44%)	(100)100%
Negative	10(55.55%)	1(0.05%)	0

The increasing reports on NDM-1 producing *Enterobacteriaceae* have addressed a potential threat to global health. In Iraq NDM-1 gene was report in *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii* (Poireletal2011; AL-Harmoosh and Jarallah2014; Anoar eta 2014; Alshara *et al* 2013; Till now there are no published works in Iraq reporting NDM-1 gene in *E.coli* The present study gives an initial insight on the incidence of bla NDM-1 gene in the clinical isolates of *E. coli*. The presence of NDM-1 gene was detected by conventional PCR technique. PCR analysis for NDM-1 gene was accomplished for the 17 *E.coli* isolates only one isolates was lake to plasmid and the NDM-1 gene are found in 14 (77.77%) isolates table

4. This increase in gene frequency because gene for this enzymes are often carried on the plasmid, facilitating rapid spread between microorganisms (Chagas *et al.*, 2011) and NDM-enzymes are very frequent in the human population and can even be found in the environment (Nordmann *et al.*, 2011). The distribution of plasmid-mediated NDM-1 gene within study isolates are shown in Figures 4, The NDM-1 gene was not detected in the remaining isolate that identified as MBLs producer by the phenotypic method. As the PCR is the gold standard technique. So, the phenotypic result may be a false positive result, or the isolates had MBLs variants or other carbapenemase genes not detected by the primers used in this study.

Table 3 .Present of NDM-1 gene in *E.coli* isolates.

Total	NDM-1 gene present	NDM-1 gene absent	Plasmid absent
18(100%)	14(77.77%)	3(16.66)	1(5.55%)




Figure. 4 Ethidium bromide stained agarose gel showing PCR Amplification products with NDM -1gene (621bp).

bla NDM-1 specific amplicons were sequenced only three isolates (*E.coli* 1, *E.coli* 11 *E.coli* 15) which have different pattern of antibiotic resistant. The DNA sequence identity was confirmed using BLASTN analysis. These three DNA sequences together with four similar sequences, retrieved from NCBI Gen Bank database under accession numbers (KR872634.1, KR872624.1, NC023908.1, JN255860) .were used to

construct the phylogenetic tree in order to understand the nearest neighbor of the study sequences. The genetic divergence and homogeneity of the sequences are apparent in the phylogenetic tree Figure 5 these sequences were closely placed in the phylogenetic tree and their genetic similarity with four sequences reported from India.




Figure: 5. Phylogenetic analysis based on bla NDM-1 gene sequences obtained from the three *E. coli* isolates in this study and four sequences retrieved from GenBank database (NCBI).

REFERENCE

1. AL-Harmoosh, Raad, Abdulbass; And Eman, M. Jarallah. First de-tection of theblaNDM-1 and bla NDM-2 genes in a clinical isolate s of *Acinetobacterbaumannii* in Hillah hospitals-Iraq.Internation al Journal of Advanced Resear ch., 2014; 10: 1407–1416.
2. Alshara,Jamal,Mohammed;Zuha-irSadiq,R.Alsehlawi;Dheyaa,Shnan,A,Aljameel;Zee naSh.AlZubb-eddy; ; and Ali, M. Almohana.First report of new delhi metallo-beta-lactamas(ndm-1)producing *Pseu -domonas aeruginosa* in Iraq journal of biology, agriculture and healthcare, 2014; 4(14): 2224-3208.
3. Anoa,Khanda,Abdulateef;Fattma, Abodi,Ali;Sherko,Ali,Omer.Det-ection of metallo - β -Lactamase enzyme in some gram negative bacteriali solated from burn patients in sulaimani city, Iraq. European Scientific Journal January., 2014; 10(3): 1857–7881.
4. Cantón, R.; Akóva, M.; Carmeli, Y.; Giske, C.G.;Glupczynski, Y.; Gniadkowski, MRapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe.ClinMicrobialInfect, 2012; 18: 413–431.
5. Chagas, T.P.; Seki, L.M.; Cury, J.C.;Oliveira, J.A.;Davila, A.M and Silva, D.M. Multi resistance, beta-lactamase-encoding genes and bacterial diversity in hospital wastewater in RiodeJaneiro, Brazil. J. Appl. Microbiol, 2011; 111(3): 572-581.
6. Falagas, M.E.; and Karageorgopoulos, D.E. Extended-spectrum beta lactamase-producing organisms. J Hosp. Infect, 2009; 73: 345–354.
7. Hong, T.; Moland, E.S.; Abdalhamid, B.; Hanson, N.D.; Wang, J.; Sl oan, C.*Escherichiacoli*:develop-ent of carbapenem resistance dur- ing therapy .Clin.Infect. Dis., 2005; 40: 84–86.
8. Lartigue, M. F.; Poirel, L.; Poyart, C.; Réglier-Poupet, H.; and Nordmann, P. Ertapenem resistance of *Escherichia coli*. Emerging Infect Dis. 2007; 13: 315–317.
9. Livermore, DM.; Walsh, TR.; Toleman, M.; Woodford, N. Balkan NDM-1:escape or transplant? Lancet Infect Dis2011 11(3):164.
10. Nordmann, P.; Naas, T.; Poirel, L. Global spread of carbapenemase producing Enterobacteriaceae. Emerg Infect Dis., 2011; 17: 1791–1798.
11. Oteo,J.; Delgado-Iribarren, A.; Vega,D.; Bautista, V.; Rodríguez, M.C.; Velasco, M. Emergence of imipenem resistance in clinical *Escherichia coli* during therapy. Int. J Antimicrob. Agents, 2008; 32: 534–537.
12. Poirel, L.; Fortineau, N.; Nordmann, P. International transfer of NDM-1-producing *Klebsiella pneumoniae* from Iraq to France. Antimicrob Agents Chemother, 2011; 55: 1821-1822.
13. Poirel, L.;Héritier, C.;Spicq, C.; and Nordmann, P. In vivo acquisition of high level resistance to imipenem in *Escherichia coli*. J Clin Microbiol, 2004; 42: 3831–3833.
14. Rahmati,Roodsari, M; Fallah ,F;Taherpour, A; HakemiVala, M; Hashemi, A.Carbapenem -resistant bacteria and laboratory detection methods. Archives of Pediatric Infectious Diseases., 2013; 1(4): 188–191.
15. Simner ,Patricia, J. ; Matthew, W.; Gilmour, Pat De Gagne, Kim Nichol, James A. Karlowsky.Evaluation of Five Chromogenic Agar Media and the Rosco RapidCarb Screen Kit for Detection and Confirmation of CarbapenemaseProduction in Gram-Negative Bacilli.J Clinical Microbiology, 2014; 53: 105-112.
16. Spanu, T.;Luzzaro, F.; Perilli, M.; Amicosante, G.; Toniolo, A.; Fadda, G.; and the Italian ESBL Study Group. Occurrence of extended-spectrum β -lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β -lactams and other antimicrobial drugs. Antimicrobial Agents and Chemotherapy, 2002; 46(1): 196-202.
17. Ullah, F.; Malik, S.A.; and Ahmed, J. Antibiotics susceptibility pattern and ESBLs prevalence in nosocomial *Escherichia coli* from urinary tract

- infections in Pakistan. *Afr.J.Biotechnol*, 2009; 8: 3821-3926.
18. Walsh, TR; Toleman, MA; Poirel, L; Nordmann, P. Metallo- β -lactamases: the quiet before the storm? *ClinMicrobiol Rev.*, 2005; 18: 306–325.
 19. Yong, D; Toleman,MA; Giske, CG; Cho, HS;Sundman, K. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrobial Agents Chemother*, 2009; 53: 5046–5054.